España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Louise Chen
How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low
Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth
Pfizer's Late-Stage COVID-19 Vaccine Data In Adolescents Reinforces Bull Case, Analyst Says
Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth
Pfizer's Late-Stage COVID-19 Vaccine Data In Adolescents Reinforces Bull Case, Analyst Says
Pfizer-BioNTech Plan Vaccine Emergency Use Filing Within Days After Final Analysis Confirm Efficacy, Safety
A Pfizer Analyst's 3 Possible Coronavirus Vaccine Readout Scenarios
Pfizer-BioNTech Plan Vaccine Emergency Use Filing Within Days After Final Analysis Confirm Efficacy, Safety
A Pfizer Analyst's 3 Possible Coronavirus Vaccine Readout Scenarios
Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward
Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential
Read More...
Louise Chen Recent News
4 Takeaways On Pfizer's Latest Coronavirus Data
The data shows more positives about Pfizer’s (NYSE: PFE) coronavirus vaccine candidate and remains in-line with its German partner BioNTech’s (NASDAQ: BNTX) study, according to Cantor Fitzgerald Secur
Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'
Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa.
Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals
Pfizer Inc.
Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development
Merck & Co., Inc. (NYSE: MRK) announced a trio of initiatives Tuesday to combat the coronavirus pandemic.
Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut
Merck & Co., Inc. (NYSE: MRK) shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance.
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
Merck To Spin Off Slow-Growing Women's Health, Legacy, Biosimilars Businesses: What You Need to Know
After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target
Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated
Amarin Shares Climb Following In-Line Review Of Fish Oil Pill By FDA Staffers
Mylan's Disappointing Outlook Rattles Analysts, Investors
Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
Analyst: Why The Sucampo Deal Is A Smart Move For Mallinckrodt
Valeant Investors: Cantor Says It's Time To Stop Waiting For The Other Shoe To Drop
UPDATE: Guggenheim Securities Reiterates on Cadence Pharmaceuticals as Earnings Visibility for Ofirmev Improves
Johnson & Johnson (JNJ) Woes Benefit Perrigo (PRGO)
Teva Pharmaceuticals Industries Ltd. (TEVA) Quarterly EPS Estimates For 2010 Revised